XML 39 R29.htm IDEA: XBRL DOCUMENT v3.8.0.1
Business, Basis of Presentation, Business Combinations, Divestitures, License/Supply Agreement and Merger (Details Textual) - USD ($)
 1 Months Ended 3 Months Ended 9 Months Ended
Oct. 05, 2015
Oct. 31, 2017
Mar. 31, 2017
Oct. 31, 2015
May 31, 2015
Mar. 31, 2018
Mar. 31, 2017
Mar. 31, 2018
Mar. 31, 2017
Jun. 30, 2017
Sep. 30, 2015
May 20, 2015
Business, Basis of Presentation, Business Combinations, Divestitures, License/Supply Agreement and Merger (Textual)                        
Stockholders' equity, reverse stock split, description               On June 8, 2015, we reincorporated as a domestic Delaware corporation under the Delaware General Corporate Law and changed our name from Rosewind Corporation to Aytu BioScience, Inc., and effected a reverse stock split in which each common stockholder received one share of common stock for every 12.174 shares held. On June 30, 2016, Aytu effected another reverse stock split in which each common stockholder received one share of common stock for every 12 shares held. On August 25, 2017, Aytu effected a third reverse stock split in which each common stockholder received one share of common stock for every 20 shares held (herein referred to collectively as the "Reverse Stock Splits"). All share and per share amounts in this report have been adjusted to reflect the effect of these Reverse Stock Splits.        
Contingent consideration           $ 6,162,337   $ 6,162,337   $ 7,386,782    
Amortization of intangible assets           387,606 $ 437,013 1,157,258 $ 1,311,043      
Inventory from primsol business       $ 102,000                
Cash           12,100,000   12,100,000        
Primsol [Member]                        
Business, Basis of Presentation, Business Combinations, Divestitures, License/Supply Agreement and Merger (Textual)                        
Upfront amount       142,000                
Inventory from primsol business $ 102,000                      
Work-in-process inventory 80,000                      
ProstaScint [Member]                        
Business, Basis of Presentation, Business Combinations, Divestitures, License/Supply Agreement and Merger (Textual)                        
Net identifiable asset acquired                       $ 2,391,000
Contingent consideration                     $ 227,000  
Upfront amount         $ 1,000,000              
Maximum aggregate payout for sale         2,500,000              
Contingent consideration valued         664,000              
Transfer of related product inventory         500,000              
Contingent consideration was initially revalued           30,000   30,000        
Amortization of intangible assets           16,000 40,000 40,000 120,000      
Percentage of net sales   8.00%                    
Contingent consideration accretion           19,000   19,000        
ProstaScint [Member] | Developed Technology Rights [Member]                        
Business, Basis of Presentation, Business Combinations, Divestitures, License/Supply Agreement and Merger (Textual)                        
Amortization of intangible assets               54,000        
ProstaScint [Member] | Trade Names [Member]                        
Business, Basis of Presentation, Business Combinations, Divestitures, License/Supply Agreement and Merger (Textual)                        
Amortization of intangible assets               7,000        
ProstaScint [Member] | Customer Contracts [Member]                        
Business, Basis of Presentation, Business Combinations, Divestitures, License/Supply Agreement and Merger (Textual)                        
Amortization of intangible assets               0        
ProstaScint [Member] | Discounted Cash Flow Method [Member]                        
Business, Basis of Presentation, Business Combinations, Divestitures, License/Supply Agreement and Merger (Textual)                        
Contingent consideration was initially revalued                   $ 54,000    
Jazz Pharmaceuticals, Inc [Member]                        
Business, Basis of Presentation, Business Combinations, Divestitures, License/Supply Agreement and Merger (Textual)                        
Share-based payment               7,400        
Inventory from primsol business               11,300        
Jazz Pharmaceuticals, Inc [Member] | Prosta Scint [Member]                        
Business, Basis of Presentation, Business Combinations, Divestitures, License/Supply Agreement and Merger (Textual)                        
Net identifiable asset acquired         $ 2,400,000              
Jazz Pharmaceuticals, Inc [Member] | Prosta Scint [Member] | Developed Technology Rights [Member]                        
Business, Basis of Presentation, Business Combinations, Divestitures, License/Supply Agreement and Merger (Textual)                        
Intangible assets                       790,000
Jazz Pharmaceuticals, Inc [Member] | Prosta Scint [Member] | Trade Names [Member]                        
Business, Basis of Presentation, Business Combinations, Divestitures, License/Supply Agreement and Merger (Textual)                        
Intangible assets                       80,000
Jazz Pharmaceuticals, Inc [Member] | Prosta Scint [Member] | Customer Contracts [Member]                        
Business, Basis of Presentation, Business Combinations, Divestitures, License/Supply Agreement and Merger (Textual)                        
Intangible assets                       $ 720,000
Primsol [Member]                        
Business, Basis of Presentation, Business Combinations, Divestitures, License/Supply Agreement and Merger (Textual)                        
Net identifiable asset acquired 1,799,000                      
Upfront amount       500,000                
Transfer of related product inventory       40,000                
Amortization of intangible assets           $ 0 61,000 $ 0 184,000      
Primsol [Member] | Selling, General and Administrative Expenses [Member]                        
Business, Basis of Presentation, Business Combinations, Divestitures, License/Supply Agreement and Merger (Textual)                        
Recognized gain     $ 428,000                  
Cash     $ 1,750,000       $ 1,750,000   $ 1,750,000      
Primsol [Member] | Paid On April Two Thousand Sixteen [Member]                        
Business, Basis of Presentation, Business Combinations, Divestitures, License/Supply Agreement and Merger (Textual)                        
Upfront amount       500,000                
Primsol [Member] | Paid on July ,2016 [Member]                        
Business, Basis of Presentation, Business Combinations, Divestitures, License/Supply Agreement and Merger (Textual)                        
Upfront amount       500,000                
Primsol [Member] | Paid in November 2016 [Member]                        
Business, Basis of Presentation, Business Combinations, Divestitures, License/Supply Agreement and Merger (Textual)                        
Upfront amount       $ 250,000                
Primsol [Member] | Developed Technology Rights [Member]                        
Business, Basis of Presentation, Business Combinations, Divestitures, License/Supply Agreement and Merger (Textual)                        
Intangible assets 520,000                      
Primsol [Member] | Trade Names [Member]                        
Business, Basis of Presentation, Business Combinations, Divestitures, License/Supply Agreement and Merger (Textual)                        
Amortization of intangible assets 140,000                      
Primsol [Member] | Customer Contracts [Member]                        
Business, Basis of Presentation, Business Combinations, Divestitures, License/Supply Agreement and Merger (Textual)                        
Intangible assets $ 810,000